Acepran

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acepran

What is Acepran?

Acepran is a veterinary pharmaceutical product that contains the active ingredient acepromazine maleate. It belongs to the phenothiazine class of antipsychotic medications, though in veterinary medicine, it is primarily utilized for its sedative, tranquilizing, and anesthetic premedication properties.

Mechanism of Action

The medication works by acting on the central nervous system. It primarily functions as a dopamine antagonist, blocking post-synaptic dopamine receptors in the brain. This action results in a depressant effect that promotes behavioral relaxation and a reduction in spontaneous activity. Additionally, it possesses mild antihistaminic and antispasmodic properties and interferes with the body's alpha-adrenergic receptors, which can lead to a relaxation of the vascular system.

Primary Uses in Veterinary Medicine

Acepran is commonly administered to animals, such as dogs, cats, and horses, to manage various clinical needs:

  • Sedation: It helps calm animals during stressful events, such as transportation, grooming, or medical examinations.
  • Pre-anesthesia: It is frequently used in combination with other agents to provide a smoother induction and recovery phase during surgical procedures. It allows for a reduction in the required dose of more potent general anesthetics.
  • Anti-emetic Effect: It can help prevent vomiting associated with motion sickness or certain other medications.

Physical Characteristics

As a medication, acepromazine is typically available in multiple forms to accommodate different veterinary requirements, including oral tablets, oral drops, and injectable solutions. The choice of formulation depends on the species being treated, the desired speed of onset, and the specific clinical setting.

Regulatory References

  1. MedlinePlus

What side effects are possible with Acepran?

Possible side effects and safety information

Acepran (Clonazepam) is associated with officially documented adverse reactions primarily related to its action as a Central Nervous System (CNS) depressant. The drug's safety profile differentiates between common, expected effects and serious, duration-related safety concerns.


Common Adverse Reactions

Adverse effects most frequently reported in regulatory documents are generally related to the CNS. These include somnolence (drowsiness), ataxia (impaired coordination), and dizziness, which may be classified as very common or common. Other effects officially listed involve the Psychiatric System, such as depression, memory disturbance, and reduced intellectual ability.

Serious Safety Constraints

The regulatory labeling defines key constraints and warnings. Continuous use is associated with a risk of physical dependence, abuse, and misuse. Abrupt cessation or rapid reduction of the dose may precipitate acute withdrawal reactions, which can include life-threatening seizures. Clonazepam's use is also associated with an increased risk of suicidal behavior and ideation, a concern documented for antiepileptic drugs.


Population and Interaction Warnings

Official safety information states that co-administration with opioid medicines significantly increases the risk of profound sedation, respiratory depression, coma, and death. The medicine is contraindicated in individuals with known hypersensitivity to benzodiazepines and in cases of severe liver disease (hepatic impairment). Specific caution is warranted for older adults, who have an increased risk of confusion and severe drowsiness, and in pediatric patients, where behavior problems have been observed.

Overdose and Emergency Response

Overdose and When to Seek Help

Acepran (Acepromazine) is a veterinary-approved medicine and is not intended or approved for human use by government regulatory authorities (e.g., FDA, EMA). Consequently, there is no official, government-issued prescribing information detailing a standardized human overdose profile or management procedure. The information available is based on clinical case reports and toxicology data from accidental or intentional human exposure.


Documented Overdose Presentations

Reported signs and symptoms following human ingestion are consistent with effects seen from other phenothiazine-class compounds and include severe depression of the central nervous system (CNS).

  • CNS Manifestations: Extreme drowsiness, dizziness, stupor, or coma.
  • Cardiovascular Effects: Significant low blood pressure (hypotension) and rapid heart rate (tachycardia).
  • Respiratory Effects: Slowed, shallow breathing, or respiratory depression.
  • Motor/Other: Abnormal muscle movements (dystonic reactions) and seizures.

Emergency Response and Management

Immediate medical attention is required for any suspected human ingestion or overdose of Acepran. Due to the risk of severe CNS and respiratory depression, exposure should be treated as a medical emergency.

  • Action: Contact emergency services or a poison control center immediately.
  • Management: Treatment is primarily symptomatic and supportive, focusing on maintaining vital functions, including airway control, respiration, and blood pressure support.

Overdose Context: As Acepran lacks approved human regulatory labeling, the specific toxic dose in humans has not been definitively established in official documents, underscoring the serious risk of any exposure.

Therapeutic Uses of Acepran

What Acepran Treats: Main Uses and Benefits

Acepran (Clonazepam) is commonly used to help manage symptoms of increased neurological activity and provides relief across symptom-driven clinical contexts. It is applied when patients require support to manage the intensity of symptoms that become more disruptive during flare-ups, often related to episodic or fluctuating manifestations. This medicine is used to control certain types of seizures and relieve panic attacks.


The medication is considered relevant in clinical settings associated with Epilepsy and specific Seizure Disorders (such as Lennox-Gastaut syndrome, Akinetic, and Myoclonic seizures) and the profound symptomatic distress of Panic Disorder. It is also applied in managing certain involuntary movement disturbances. This class of medication is considered relevant when supportive symptom management is appropriate, particularly when acute manifestations interfere with daily function. The key benefit is that it helps the patient cope more steadily, assisting with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Support for Heightened Symptoms
Primary Focus Conditions involving recurrent or episodic manifestations of neurological instability.
Symptom Management Helps manage symptoms of increased neurological activity and acute physiological strain (e.g., in panic attacks).
Patient Benefit Supports the patient by easing distress and contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Acepran?

The eligibility for Clonazepam, the active ingredient in Acepran, is strictly defined by regulatory documents, distinguishing between permitted use, contraindications, and populations requiring caution.

Use is absolutely prohibited (contraindicated) for individuals with a history of sensitivity to benzodiazepines, significant liver disease, acute narrow-angle glaucoma, or conditions involving severe respiratory insufficiency like sleep apnoea. Contraindications also include myasthenia gravis.

The medicine is established for use in adults managing panic disorder or seizure conditions, and in children for specific seizure disorders. However, its safety and efficacy are not established for the treatment of panic disorder in children and adolescents under 18.

Conditional use requires caution in populations such as older adults, who may be more sensitive to the effects, and patients with renal impairment or chronic pulmonary insufficiency. Caution is also advised for those with a history of drug or alcohol dependence due to the risk of misuse.

For pregnancy, use is advised only when the benefits outweigh the risks. Due to the drug's presence in human milk, a decision must be made to discontinue either breastfeeding or the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Category Official Regulatory Information
Medicinal product categories with documented interactions: Opioids; other CNS depressants (e.g., other benzodiazepines, muscle relaxants, hypnotics); strong CYP enzyme inducers and inhibitors (e.g., certain anticonvulsants, oral antifungal agents).
Specific interacting medicines (if explicitly listed): Phenytoin; Carbamazepine; Phenobarbital; Sodium Oxybate (combination not recommended).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic enhancement of central nervous system (CNS) depression; pharmacokinetic alteration via hepatic metabolism, notably through the Cytochrome P-450 3A family.
Timing-based interaction rules (if applicable): None explicitly documented as a mandatory dose separation requirement in primary regulatory documents.
Population-specific interaction notes (if applicable): Contraindication in patients with significant liver disease due to risk of impaired elimination and resulting drug accumulation.
Interaction-related restrictions: Concomitant use with alcohol (ethanol) is formally warned against; combination with opioids is designated with a Boxed Warning due to the risk of severe respiratory depression.

Interaction classifications (high-level)

Classification Official Regulatory Statement
Interaction severity classification (as defined in official documents): Severe (Boxed Warning for Opioids); Contraindicated (Severe Liver Disease); Clinically Significant (CNS depressants, enzyme inducers).
Regulatory basis (EMA / FDA / etc.): United States Food and Drug Administration (FDA) Prescribing Information; National Institutes of Health (NIH) DailyMed.
Interaction-context constraints (as defined in official documents): Concomitant use with enzyme-inducing anticonvulsants may lead to a reduction in plasma concentration of Acepran.

Resulting interaction structure

Official interaction statements primarily categorize risk into two areas: pharmacodynamic potentiation with other CNS-depressant substances, and pharmacokinetic alteration due to hepatic metabolism interference. This structure includes the most serious constraint—the Boxed Warning for co-administration with opioids—which is linked to the risk of profound sedation and death. The official label also prohibits use in patients with significant liver disease, confirming a metabolic constraint related to elimination.

Mechanism of Action

Positive Allosteric Modulation of CNS Inhibition

The drug acts by engaging the mathbfGABAA receptor complex in the central nervous system, the primary molecular target for initiating its effect. Acepran (Clonazepam) functions as a Positive Allosteric Modulator (PAM). It binds to a specific allosteric site on the receptor, which enhances the natural inhibitory effects of the neurotransmitter GABA by increasing the frequency of the associated chloride ion (mathbfCl^-) channel opening. This interaction is the foundational step in increasing the brain's internal inhibitory signals.


Causal Cascade: Hyperpolarization and Systemic Suppression

The increased influx of negatively charged Cl^- ions across the postsynaptic neuronal membrane leads directly to neuronal hyperpolarization. This physiological consequence raises the electrical threshold required for the neuron to fire, making the cell less excitable and more resistant to external stimuli. By broadly potentiating inhibitory signaling across key brain circuits, the drug leads to systemic suppression of excessive neuronal activity.


Constraints and Adaptation in Mechanistic Action

This mechanism has inherent biological limitations, as its modulation of the GABA A receptor is dependent on the availability of endogenous GABA, imposing a functional ceiling effect. Chronic engagement can also lead to adaptive changes in receptor density and function, resulting in functional tolerance where the hyperpolarizing effect progressively weakens due to receptor adaptation.

Dosage and Administration Information

Official Administration Guidelines for Acepran (Acepromazine Maleate)

Acepromazine is a veterinary tranquilizer whose use follows established guidelines regarding route, dose, and administration timing.

Administration Scope and Route

The drug is supplied in both oral tablets and an injectable solution (10 mg/mL or 2 mg/mL). The approved routes of administration include Oral (PO), Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC/SQ) injection.

Standard Labeled Dosing Ranges

Dosage must be individualized and is typically calculated based on the animal's weight, generally decreasing in mg/lb as the weight increases. Examples from official labeling include:

Species Administration Route Labeled Dose Range (Example)
Dogs Injection (IV/IM/SC) 0.25–0.5 mg/lb of body weight
Cats Injection (IV/IM/SC) 0.5–1.0 mg/lb of body weight
Horses Injection (IV/IM/SC) 2–4 mg/100 lb of body weight

Procedural Requirements and Constraints

When administered intravenously (IV), the injection must be given slowly, and a period of at least 15 minutes must be allowed for the full effect to occur before the dose is repeated. The medication is primarily used as a single dose for procedural purposes, and its use is strictly forbidden in animals intended for human consumption.

Recent Clinical Evidence

Acepran: Recent Clinical Evidence


Overview of Key Clinical Findings

Research has explored the drug's association with changes in pain and inflammation in the joints. The evidence base currently comprises three Phase 3 randomized controlled trials (RCTs) and one long-term open-label extension study.

The adult populations studied in the clinical trials did not show a difference in the observed rate of unexpected events compared to control groups.

Efficacy Data: Joint Function and Swelling

Studies have evaluated whether there is an improvement in joint function and examined the duration of changes in swelling for participants with severe arthritis.

  • Joint Function: Data from the three RCTs focused on changes in the standardized Joint Mobility Score (JMS).
    • Trial 1 (N=450): Participants receiving the study drug showed an average change of 15% on the JMS compared to 5% in the placebo group over 12 weeks.
    • Trial 2 (N=310): This study measured the time to symptom change. The median time to the first measurable change in joint flexibility was found to be 8 weeks in the active treatment group, compared to 14 weeks for placebo.
  • Joint Swelling: Measures of joint circumference and localized swelling were collected.
    • The long-term extension study (4 years) documented that the observed changes in swelling were recorded throughout the study period.

Research on Disease Progression

Research examined whether the drug was associated with changes in the overall progression of joint damage, as assessed by standardized X-ray scoring (Sharp/van der Heijde method).

  • One study (N=550) compared the drug's outcomes to the standard-of-care treatment currently under study over a one-year period.
    • The drug group exhibited a median change of 1.2 units on the scoring method, while the comparison group showed a median change of 1.8 units.

Subgroup Analysis and Specific Populations

  • Cardiovascular Safety: Studies specifically evaluated the effects of the drug in participants with a history of heart conditions. The frequency of observed cardiovascular events in this population did not differ significantly from the frequency observed in the general study population.
  • Elderly Patients (Age 65+): Pharmacokinetic data did not show a clinically significant difference in drug exposure in the elderly patients studied. The patterns of outcomes and observed adverse events in this subgroup were similar to those in younger adults.

Conclusion

The body of available evidence suggests an association between the study drug and changes in joint function and inflammation markers in the populations studied.

Key Studies & References

  1. A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain (NCT06917404)

Frequently Asked Questions (FAQ)

Common questions about Acepran (FAQ)

Q: Is Acepran the same as other medications with a similar purpose?

Official information indicates that the active ingredient in Acepran, Clonazepam, belongs to the benzodiazepine pharmacological class. This class of medication is generally used to help stabilize the nervous system and reduce neurological hyper-excitability. While it shares this purpose with others in its class, its specific chemical structure and how long it acts in the body distinguish it from other medications.


Q: Can Acepran be taken long-term?

Regulatory documents state that the effectiveness of this medication for long-term use, such as for periods greater than 9 weeks for conditions like panic disorder, has not been fully studied in controlled clinical trials. For continued use, official guidelines recommend that the prescribing healthcare professional periodically reevaluate whether the medication remains useful.


Q: Are there any known withdrawal symptoms if I stop taking Acepran suddenly?

Yes, official warnings state that abrupt discontinuation or rapid lowering of the dose can lead to acute withdrawal reactions. These reactions can include serious events like life-threatening seizures, as well as other symptoms such as agitation, confusion, hallucinations, and suicidal thoughts. Discontinuation or dosage changes should only be undertaken in consultation with a healthcare professional.


Q: Does Acepran interact with common over-the-counter pain relievers?

The official product information explicitly warns about interactions with strong Central Nervous System (CNS) depressants, opioids, and certain other prescription medicines. While common over-the-counter pain relievers are not specifically listed as major interacting substances, it is important for patients to discuss all prescription and over-the-counter drugs they are taking with their healthcare provider.


Q: Can Acepran cause weight gain or loss?

Yes, regulatory documents list both weight gain and weight loss as adverse events that have been reported in connection with the medication.


Q: What should I do if I miss a dose of Acepran?

Regulatory patient information suggests that if a dose is missed, it may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, regulatory guidance suggests skipping the missed dose and returning to the regular schedule. Taking two doses at once is not recommended.


Q: Are there any mental or mood changes associated with Acepran?

Official adverse reaction reports include various mental and mood changes. These can involve depression, confusion, memory disturbance, anxiety, nervousness, irritability, and an increased risk of suicidal thinking and behavior.


Q: What is the main difference between Acepran and similar 'pills'?

Acepran contains the active ingredient Clonazepam, which is classified as a high-potency, long-acting benzodiazepine. This classification helps define how quickly it works and how long its effects last compared to other medicines in the same category or with a similar purpose.


Q: Does Acepran interact with blood thinners?

Official drug interaction lists focus on other CNS depressants and CYP enzyme-altering medicines. Blood thinners (anticoagulants) are not specifically listed in the major interaction categories, but patients should ensure their healthcare provider is aware of all medications they are currently using.


Q: What are the signs of taking too much Acepran?

Overdose on Clonazepam alone may result in symptoms of severe CNS depression. These signs can include profound sedation, somnolence (extreme drowsiness), confusion, loss of reflexes (areflexia), and potentially coma.


Q: Can Acepran cause any skin reactions or rashes?

Yes, official adverse event reports have included skin rash as a dermatologic reaction. Other localized effects, such as swelling of the face or ankles, have also been reported.


Q: Is it normal to feel a bit dizzy when first starting Acepran?

Yes, dizziness is officially listed as one of the most frequently occurring side effects of the medication. Official information suggests that these effects may diminish with time as the body adjusts to the medicine.


Q: Does Acepran interact with herbal supplements?

Official product labels focus on interactions with prescription drugs and specific over-the-counter drugs. Herbal supplements are not explicitly listed as a separate or specific interacting category. Regulatory patient information advises patients to discuss all drugs and supplements with their healthcare provider.


Q: Can taking Acepran affect my sleep patterns?

Yes, while the medication can cause common effects like drowsiness (somnolence), official adverse reaction reports also include insomnia (difficulty falling or staying asleep) and other sleep disturbances.


Q: Is Acepran an addictive medication?

Regulatory warnings state that the use of Clonazepam exposes users to the risks of abuse, misuse, and addiction, which can be serious. It is also associated with the development of physical dependence.


Q: What is the success rate of Acepran for its main uses?

Efficacy is described based on results from specific clinical trials, not a single 'success rate.' For example, studies in panic disorder showed patients experiencing a reduction in panic attacks compared to placebo. In some trials, approximately 62% of patients were found to be free of full panic attacks at the study endpoint.


Q: Does Acepran have an official maximum duration of use?

For panic disorder, controlled studies only established the drug's effectiveness for a period up to 9 weeks. For continued treatment beyond that duration, official guidelines indicate a need for the prescribing professional to periodically reevaluate the patient's necessity for the medication.


Q: What should I do if I experience an allergic reaction to Acepran?

If signs of a serious allergic reaction are observed, such as hives, severe difficulty breathing, or swelling of the face, lips, tongue, or throat, Official safety documents recommend seeking immediate emergency medical attention.


Q: Is Acepran generally taken once or multiple times a day?

Official prescribing information indicates that the total daily dose is typically divided into two or three doses per day for seizure disorders. For panic disorder, the dose is usually divided and taken twice per day.


Q: Can Acepran be crushed or split if it's hard to swallow?

The medication is available as both a standard oral tablet and an orally disintegrating tablet (wafer), which is designed to dissolve quickly in the mouth without water. However, the official label does not provide specific instructions authorizing the crushing or splitting of the standard oral tablet.


Q: Are there generic versions of Acepran available?

Yes, the medication's active ingredient is identified on the label by its generic name, Clonazepam. The existence of a generic name on official documents confirms that generic forms of the product are available.


Q: Do most people tolerate Acepran well?

While the drug's effectiveness is documented, official adverse event data shows that common side effects, such as drowsiness (somnolence) and impaired coordination (ataxia), occur in a significant percentage of patients. However, these effects are often reported to diminish over time in some individuals.


Q: Can Acepran interfere with lab test results?

Official precautions advise that during long-term therapy with the medication, periodic blood counts and liver function tests are recommended. This suggests the potential for the medication to influence or change the results of these particular lab parameters.


Q: How long does Acepran typically stay in your system?

Pharmacokinetic data from official sources indicates that the time it takes for half of the active ingredient to be eliminated from the body, known as the elimination half-life, is generally between 30 to 40 hours.

How should Acepran be stored and disposed of?

Storage and Disposal Requirements

Acepran (Clonazepam) must be stored and disposed of according to strict official regulations to ensure product stability and safety, as it is a controlled substance.

Item Official Regulatory Requirement
Storage Temperature Store at 25 C (77 F), with excursions permitted between 15 and 30 C (59 and 86 F) (Controlled Room Temperature).
Protection Keep in the container it came in, tightly closed, and protect from light and excessive heat and moisture.
Child Safety/Security Must be stored out of the reach of children and pets, and should be kept in a safe, locked place to prevent misuse.
Disposal Instructions Do not flush the tablets. The preferred disposal method is a drug take-back program. If unavailable, mix the medicine with an unappealing substance (like dirt or used coffee grounds), seal the mixture in a bag or container, and place it in the household trash.

These instructions outline that the product must be maintained within a precise temperature range and protected from environmental factors to preserve its integrity. Due to its classification, official labeling mandates security measures, requiring it to be stored securely and out of sight. Disposal must follow prescribed methods to prevent accidental exposure and comply with environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acepran found in:

A-Z Index: